Auxilium Pharmaceuticals — Investor Presentation (September 2011)
50 slides from Auxilium Pharmaceuticals's investor presentation, Sep 13, 2011
Slide 1: Auxilium - Innovations for Life
AUXILIUM Innovations for Life TM September 2011 (NASDAQ: AUXL)
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks relating to our current plans, potential future events, and what we believe to be the prospects for the Company during this conference call that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Secur
Slide 3: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Shareholder Value Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 4: XIAFLEX and Testim Are Global Product Opportunities
XIAFLEX and Testim Are Global Product Opportunities U.S. Canada EU Japan Open ROW Open Open Territory XIAFLEX Testim
Slide 5: Auxilium Has a 6 Year Net Revenue CAGR of 42.5%
Auxilium Has a 6 Year Net Revenue CAGR of 42.5% $- $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 $70,000 Q3 03 Q4 03 Q1 04 Q2 04 Q3 04 Q4 04 Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 N
Slide 6: XIAFLEX
XIAFLEX Collagenase clostridium histolyticum PARADIGM CHANGING TREATMENT
Slide 7: Dupuytren's Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care
Dupuytren’s Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care •Excessive collagen in fascia of hand •Nodules or pits are an early, active presentation •Rope-like cords develop in the finger and result in contractures •Quality of life and daily activities affected •Su
Slide 8: We Believe XIAFLEX Is a Paradigm Changing Treatment
We Believe XIAFLEX Is a Paradigm Changing Treatment • Simple, non-invasive injection of XIAFLEX • Established mechanism of action and selective for specific types of collagen • XIAFLEX’s post-approval profile is consistent with clinical trial experience Pre XIAFLEX injection 30 days following XIAFLE
Slide 9: Strategies for Establishing XIAFLEX as the Standard of Care
Strategies for Establishing XIAFLEX as the Standard of Care •Disseminate our excellent clinical efficacy and safety data; •Facilitate peer to peer dialogue with physicians and reimbursement specialists; •Educate patients and health care providers who inject, as well as those who refer to our target
Slide 10: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs •~ 6,000 target physicians –Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists •~ 100 field based personnel –Sales reps, sales managers, and reimbursement specialists •Medical science liaisons –Key opinion lea
Slide 11: We Believe the U.S. Dupuytren's Opportunity Is Significant
We Believe the U.S. Dupuytren’s Opportunity Is Significant 70,000 Surgical 2,3,4 Patients Annually 300,000 Diagnosed Patients Annually 2,3,4 >1 Million Diagnosed Patients 2,4 1.Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2.SDI Claims Data Based Projections 3.Medicare Data Base
Slide 12: New XIAFLEX Data from ASSH 2011
New XIAFLEX Data from ASSH 2011
Slide 13: XIAFLEX U.S. Post-Marketing Safety Experience Comparable to Clinical Trial Experience
XIAFLEX U.S. Post-Marketing Safety Experience Comparable to Clinical Trial Experience •Information reported since U.S. approval of XIAFLEX –Feb 2, 2010 to June 30, 2011 •Approximately 11,000 injections administered post-approval in the U.S. –Approximately 1.1 injections per patient –Assumption: Appr
Slide 14: 71% of XIAFLEX Patients Did not Recur at Three Years
0 10 20 30 40 50 60 70 80 -300 -150 0 150 300 450 600 750 900 1050 1200 Fixed Flexion Contracture (degrees) Time (Days from Achieving 0—5 degrees) Non-Recurrent MP Joints (N=321) Recurrent MP Joints (N=96) Baseline Day Achieving 0—5 degree Year 1 cut off Year 2 cut off Year 3 cut off 21% of Joints 7
Slide 15: XIAFLEX Chart Review—Real World Outcomes Better than Clinical Trials
XIAFLEX Chart Review—Real World Outcomes with XIAFLEX Are Better than Results from Clinical Trials •In a chart review, XIAFLEX injection/joint rate of 1.09 was 36% lower in real world use, compared to clinical trial experience, with equivalent outcomes •Range of Motion and Contracture Reduction were
Slide 16: XIAFLEX Chart Review - Full Release Rates Following First Injection
XIAFLEX Chart Review- Full Release Rates Following First Injection were Higher than in Clinical Trials Retrospective Chart Abstract Study (2010) Prospective CORD 1 Trial 1 Full cord release 178* (63%) 79** (39%) Partial release 95 (34%) 116 (57%) No cord release*** 8 (3%) 8 (4%) Total 281(100%) 203
Slide 17: Multicord Proof of Concept Data
Multicord Proof of Concept Data Suggests Ability to Treat Multiple Cords Concurrently with XIAFLEX •Concurrent injection of two doses (0.58 mg) of XIAFLEX into the same hand is well tolerated –Efficacy consistent with that demonstrated with single injections –Safety profile similar to single injecti
Slide 18: Launch Update Through August 2011
Launch Update Through August 2011
Slide 19: Leading Indicators Trending Positively
Leading Indicators Trending Positively —Cumulative enrollment & sites that have ordered XIAFLEX 1994 2097 2202 2306 2400 2512 2597 2669 2765 2820 2885 2974 1422 1509 1613 1693 1758 1845 1937 2002 2077 2134 2180 2250 500 576 671 772 841 902 983 1048 1100 1156 1203 1244 0 500 1000 1500 2000 2500 3000
Slide 20: Sites Moving from Test Drive to Increasing Usage
Sites Moving from Test Drive to Increasing Usage Injections per Site Feb (902 Sites) Mar (983 Sites) Apr (1048 Sites) May (1100 Sites) June (1156 Sites) July (1203 Sites) August (1244 Sites) 0 50 100 150 200 250 300 350 400 450 500 1-2 Injections 3-10 Injections 11+ Injections 408 347 147 429 372 18
Slide 21: Quarterly XIAFLEX Revenue
Quarterly XIAFLEX Revenue (in $ millions) * Includes one-time revenue recognition change of $1.8 million $2.0 $4.6 $7.3 $8.7 $9.9 $1.1 $1.1 $1.1 $1.8 $5.5 $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 $18.0 Q2 2010 Q3 2010 Q4 2010 Q1 2011 Q2 2011 U.S. Revenues EX- U.S. and Contract Revenues$1.8*
Slide 22: We Expect the Global Dupuytren's Market to Develop in 2011 and 2012
We Expect the Global Dupuytren’s Market to Develop in 2011 and 2012 U.S. •XIAFLEX specific J-code J0775 effective Jan. 1 •U.S. CPT code guidance expected for Jan. 2012 •Additional phase IV clinical trials •Increasing peer to peer dialogue programs for U.S. physicians •Targeted U.S. patient education
Slide 23: Testim 1% Testosterone Gel
Testim® 1% Testosterone Gel •Indicated for testosterone replacement therapy in adult males for hypogonadism •Launched in U.S. in 2003 and EU in 2006 •>8 yrs of use with established safety and efficacy >~100M daily doses since launch >16 clinical studies involving approx. 1,800 patients •Applied once
Slide 24: Hypogonadism Is an Unmet Need and Under-penetrated Market
Hypogonadism Is an Unmet Need and Under-penetrated Market •39% of U.S. males over 45 yrs are hypogonadal1 >Less than 10% of affected population receives treatment •Increasing physician and patient education and awareness should result in increased treatment 1 Mulligan T. et al. Int J. Clin Pract 200
Slide 25: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $ 198 $281 $334 $371 $ 439 $545 $685 $892 $1,149 $49 $59 $ 77 $ 118 $ 210 $302 $390 $ 451 $483 $554 $663 $ 810 $1,041 0 200 400 600 800 1 , 000 1 , 200 1 , 400 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 200
Slide 26: Testosterone Replacement Therapy Landscape is Changing
Testosterone Replacement Therapy Landscape is Changing •New competition in 2011 should help increase overall market –Axiron 2% solution –Fortesta 2% gel –Androgel 1.6% gel •Expected further increase in physician and patient education and awareness
Slide 27: XIAFLEX Pipeline
XIAFLEX Pipeline
Slide 28: XIAFLEX Represents a Pipeline in a Product
XIAFLEX® Represents a Pipeline in a Product - U.S. patent protected through 2028 PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX XIAFLEX Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Canine Lipoma* Human Lipoma* Cellu
Slide 29: Peyronie's disease Is a Devastating Disorder with No Approved Therapies
Peyronie’s disease Is a Devastating Disorder with No Approved Therapies 1 Smith BH. Am J Clin Pathol. 1966;45:670-678. 2 Somers KD, Dawson DM. J Urol. 1997;157:311-315. •Scarring phenomenon affecting the tunica albuginea1 •Plaques show excessive collagen deposition2 •Potential Symptoms >Pain with er
Slide 30: Peyronie's Disease Prevalence
1 Bella A. Peyronie’s Disease J Sex Med 2007;4:1527–1538 2 Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6–23. 3 Mulhall JP, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate
Slide 31: Peyronie's Disease Phase III Development Program
Peyronie’s Disease Phase III Development Program Study Type ~ # Subjects Sites XIAFLEX: Placebo Duration AUX-CC-803 Double-blind, placebo controlled 400 ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-804 Double-blind, placebo controlled 400 ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-802 Open Label 250 12 US 6 NZ 18 EU N/A 36
Slide 32: Changes to the Phase IIb Trial Design Should Increase Chance of Phase III Success
We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III •4 cycles of therapy in the phase III trial •All patients receive modeling in the phase III trial •All patients must have greater than 12 months of disease since diagnosis to enter the phase III trial
Slide 33: Peyronie's Pivotal Phase III Update
Peyronie’s Pivotal Phase III Update •Active dosing phase complete •Entering 34 week follow-up phase of studies •Top line results in Peyronie’s should be available in 2Q12
Slide 34: Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite
Collagen Septae Enable Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite Collagen Network
Slide 35: EFP Represents an Unmet Medical Need
EFP Represents an Unmet Medical Need •Current non-surgical treatment options have not shown benefit in EFP –OTC pills, creams and lotions. –Unapproved mixtures of enzymes and fat dissolvers –Various devices, including lasers •There are currently no FDA approved medical therapies for EFP •Surgical ap
Slide 36: Early Pilot Phase I Trial was Encouraging
Early Pilot Phase I Trial was Encouraging •Drs. Dagum and Badalamente at SUNY Stony Brook •10 female subjects were treated with a single 0.58 mg dose of collagenase •76% reduction in the physician reported appearance of cellulite and a patient satisfaction score of 1.75 at 6 months –Scale for the pa
Slide 37: Considerable Work Done in Cellulite
Considerable Work Done in Cellulite •Pre-IND meeting with FDA to determine a path forward •Pre-clinical work done with subcutaneous injections of XIAFLEX at variable doses in a mini-pig study –Lysis of collagen in dermal septae was observed at all doses •Completing stability work on new diluent and
Slide 38: Cellulite – Phase Ib Dose Escalation Study
38 Cellulite – Phase Ib Dose Escalation Study •Expected to begin in 1Q12 •Assess the safety and efficacy of XIAFLEX in the treatment of cellulite –Multiple doses in various volumes and concentrations –10 injection sites over an 8 x 10cm surface area –Seven cohorts followed for 90 days •Physician and
Slide 39: Collagen Accumulation Can Result in Adhesive Capsulitis
Collagen Accumulation Can Result in Adhesive Capsulitis Normal Shoulder Frozen Shoulder
Slide 40: Adhesive Capsulitis Represents an Unmet Medical Need
Adhesive Capsulitis Represents an Unmet Medical Need •Current treatment options have limited results –non-steroidal pain relievers –oral steroids –corticosteroid injections –physical therapy all with limited results. •Manipulation of the shoulder under anesthesia or arthroscopic surgery can disrupt
Slide 41: Early Pilot Phase II Trial was Encouraging
Early Pilot Phase II Trial was Encouraging •Drs. Wang and Badalamente at SUNY Stony Brook –60 subjects treated with varying doses of collagenase –Following a single injection of collagenase, 8 subjects in the collagenase groups or approximately 16% achieved successful treatment outcomes –In the subs
Slide 42: Frozen Shoulder – Phase IIa Dose Escalation Study
Frozen Shoulder – Phase IIa Dose Escalation Study •To assess the safety and efficacy of XIAFLEX in the treatment of Frozen Shoulder –Two doses (0.29 and 0.58 mg) given under ultrasound guidance –Approximately 50 subjects across 4 cohorts –Up to three injections 21 days apart –Subjects followed for 9
Slide 43: BTC Will Advance Clinical Studies in Canine and Human Lipomas
BTC Will Advance Clinical Studies in Canine and Human Lipomas •Lipomas consist of normal fat encapsulated within a collagen capsule or shell •Current treatment options for lipoma include liposuction or surgical excision •There are no approved non-surgical therapies •We believe XIAFLEX may be benefic
Slide 44: XIAFLEX – Additional Data and Development Work Ongoing
XIAFLEX – Additional Data and Development Work Ongoing •Some small pilot studies were conducted examining the effects of collagenase on lipomas in humans and animals. •Investigators noted improvement in lipomas, specifically reduction in their size, following injections of collagenase. •BTC is plann
Slide 45: Business Development Efforts Expected to Focus on Building Out Pipeline
Business Development Efforts Expected to Focus on Building Out Pipeline •Leverage current infrastructure of Testim and XIAFLEX field forces with marketed products •Seeking Phase II and later assets in Urology, Endocrinology, Rheumatology, and Orthopedics •Niche products with specialty physician call
Slide 46: 2Q11 Financial Results ($ Millions)
2Q11 Financial Results ($ Millions) Incr. / (Decr.) 2Q11 2Q10 $ % Total Revenues $ 65.9 $ 50.5 $15.5 31% Cost of Goods Sold * $ 14.4 $ 11.5 $ 2.8 25% Gross Profit $ 51.6 $ 39.0 $ 12.6 32% % of Revenues 78% 77% R & D Expense * $ 13.3 $ 11.1 $ 2.2 20% SG&A Expense * $ 43.4 $ 41.2 $ 2.1 5% Net Loss $ (
Slide 47: 2011 Guidance
2011 Guidance Global Testim Revenues $200—210 million Xiaflex: US Revenues 45—50 million Ex US / Def Rev 9—11 million Total Xiaflex $54—61 million Total Revenues $254 – 271 million R & D Expense $60—70 million S G & A Expense $170—180 million Net Income (Loss) $(40)—(45) million Stock Base Comp Expe
Slide 48: We Believe That Auxilium is Well-Positioned for Long-Term Growth
We Believe That Auxilium is Well-Positioned for Long-Term Growth •Establish XIAFLEX as the standard of care for Dupuytren’s contracture in the U.S. •Maximize Testim in a changing competitive environment •Support Pfizer’s launch of XIAPEX for the treatment of Dupuytren’s contracture •Complete the Pey
Slide 49: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 50: Management Contact
Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com
Auxilium Pharmaceuticals — Investor Presentation (September 2011) on 6ix